AzTrials
AzTrials

ThyroidNCT04763122

Thyroid Cancer in United Arab Emirates

An observational study of Thyroid and Cancer, run by Tawam Hospital.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The main objective of the study is to assess the trend of clinicopathological features and treatment modalities in patients with thyroid cancer in the largest oncology center in the United Arab Emirates (UAE). Read more about this study

Who is it for?
Any age
Conditions the study is for
Thyroid, Cancer
What is being tested?
not applicable as it is a retrospective study
How many people
762 participants
Where
No sites listed yet
Study dates
Sep 2008to Dec 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: All patients with Thyroid Cancer presenting to Tawam Hospital during the period of September 2008 and December 2018. Those with incorrect pathological diagnosis, incomplete data, or noninvasive follicular type PTC were excluded.

Who may be able to join

  • All patients with Thyroid Cancer presenting to Tawam Hospital during the period of September 2008 and December 2018.

Who cannot join

  • Patients with inadequate data, noninvasive follicular type PTC and incorrect pathological diagnosis,

About this study

Official title: Decline in Radioiodine Use But Not Total Thyroidectomy in Thyroid Cancer Patients Treated in United Arab Emirates- A Retrospective Study

The main objective of the study is to assess the trend of clinicopathological features and treatment modalities in patients with thyroid cancer in the largest oncology center in the United Arab Emirates (UAE).

Read the detailed description

The aim of this study is to assess the trend of clinicopathological features and treatment modalities in patients with thyroid cancer (TC) in the largest oncology center in the United Arab Emirates (UAE).

This study was conducted in Tawam hospital (TWM), which provides tertiary care services to patients in the UAE. It is the only center delivering radioactive iodine (RAI) therapy and radiotherapy in Al Ain city. Most TC patients are followed in designated TC clinics within the endocrinology division or less commonly through other clinics (surgery, radiation, or medical oncology). The hospital runs monthly multidisciplinary team-based discussions on patients with TC, wherein decisions regarding RAI treatment and dose selection are determined jointly by nuclear medicine physicians and endocrinologists.

We retrospectively evaluated all patients with TC presenting to TWM during the period of September 2008 and December 2018. The beginning of data collection (September 2008) reflects the inception time of electronic medical records (EMRs) use in the hospital. Cases of TC were extracted from the EMRs using the International Classification of Disease 9 \& 10 codes (193 \& c73). Other variables were demographic information, year of diagnosis, type of TC, histopathological subtype, lymph node (LN) involvement, type of thyroid surgery, use of RAI treatment, and radiation therapy. The extent of surgery, the exact details of histopathology, and the RAI dose were retrieved from the respective specialty reports. Tumor staging was reported according to the 8th edition of the American joint committee on cancer (AJCC)/TNM staging system [16]. Those with incorrect pathological diagnosis, incomplete data, or noninvasive follicular type PTC were excluded.

The data were extracted using Microsoft Excel 2015 and imported into Stata 16.0 for statistical analysis. Continuous variables were described using means and standard deviations (±SD). Categorical variables were described as frequency distributions. Variables of clinical features and management were cross tabulated with the year of diagnosis and exact logistic and ordinal logistic regressions were performed to analyze the annual trend in features and management of TC as appropriate. The results of relative trend were reported as odds ratio (OR) with an overall ptrend. The OR=1 indicated no change over years, OR <1 indicated a decline, while OR >1 indicated an increase over years. Simple and multiple logistic regression analysis were performed to assess the unadjusted and adjusted association of management of TC (RAI, surgical management) with age, gender, nationality, year of diagnosis, tumor subtype, and other co-variates. The results of simple and multiple logistic regression were reported as odd ratios (OR) and adjusted odds ratios (AOR) respectively with their corresponding 95% confidence intervals (CI) and p-values.

Conditions
Thyroid, Cancer
Being tested
not applicable as it is a retrospective study
Keywords
Malignancy, Radioactive iodine, total thyroidectomy, Thyroid Cancer
Medical subject headings
Thyroid Diseases, Neoplasms, Thyroid Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • not applicable as it is a retrospective studyOther

    It is a retrospective study

Study groups in NCT04763122
Study groupRoleWhat they receive
Thyroid Cancer CasesNot described
Receives: Other: not applicable as it is a retrospective study

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinicopathological features

    Assess clinicopathological features of thyroid cancer patients

    Measured: September 2008- December 2018

  2. Extent of surgery

    Assess extent of surgery in thyroid cancer patients and changes over time

    Measured: September 2008- December 2018

  3. Use of RAI

    Evaluate the use of RAI in thyroid cancer patients and assess predictors of RAI Rx

    Measured: September 2008- December 2018

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Feb 2021
  2. Study startSep 2008
  3. Primary completionDec 2018
  4. Study completionDec 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Retrospective
Enrolment
762 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04763122
Sponsor's protocol ID
SA/AJ/562
Status last verified
Feb 2021
First submitted
9 Feb 2021
Last updated
21 Feb 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Thyroid and Cancer, run by Tawam Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinicopathological features (time frame: September 2008- December 2018). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2021; AzTrials last refreshed its copy on 1 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in